A regularly prescribed class of heart medications might be capable of treating one of the most common forms of muscular dystrophy, a new study in mice suggests.

Myotonic dystrophy type 1 (DM1) is caused by abnormal RNA that affects the function of calcium channel receptors, which help convert impulses from nerve cells into chemical signals that guide muscle movement, the researchers expla...

The U.S. Food and Drug Administration on Thursday approved the drug Elevidys, the first gene therapy for the treatment of children with Duchenne muscular dystrophy (DMD).

The groundbreaking treatment will not be cheap: Drugmaker Sarepta Therapeutics Inc. said it would charge $3.2 million for the one-time IV treatment, the Associated Press reported. Like most medicines in the Unit...